Effect of Baseline and Changes in Systolic Blood Pressure Over Time on the Effectiveness of Valsartan in the Valsartan Heart Failure Trial
|
|
- Logan Lang
- 5 years ago
- Views:
Transcription
1 Effect of Baseline and Changes in Systolic Blood Pressure Over Time on the Effectiveness of Valsartan in the Valsartan Heart Failure Trial Inder S. Anand, MD, DPhil, FRCP; Thomas S. Rector, PhD; Michael Kuskowski, PhD; Sabu Thomas, MD; N. J. Holwerda, MD; Jay N. Cohn, MD Background Low systolic blood pressure (SBP) is a risk factor for adverse outcomes in patients with heart failure (HF). Valsartan improved morbidity rates in the Valsartan Heart Failure Trial (Val-HeFT) despite a reduction in SBP. The aim of the present study was to investigate the relationship between the SBP-lowering effects of valsartan and its cardiovascular protective effects in this population. Methods and Results Baseline measurements and changes in SBP at 4 months were related to mortality and morbidity rates. The effects of valsartan on these end points were compared in quartiles of baseline SBP with multivariable Cox proportional hazards regression models that included a test for interaction between the effects of valsartan treatment and baseline SBP and examined the effects of changes in SBP on the valsartan effect. The mean SD baseline SBP in all patients (n 5010) was mm Hg. Patients in the lowest quartile of SBP (SBP 110 mm Hg; mean SBP 102 mm Hg; n 940) had more severe HF and a significantly increased adjusted risk of death (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.03 to 1.43; P 0.02), first morbid event (HR, 1.25; 95% CI, 1.10 to 1.40; P 0.001), and hospitalization for HF (HR, 1.45; 95% CI, 1.22 to 1.73; P 0.001) than did patients in the upper 3 quartiles of baseline SBP (mean SBP 130 mm Hg; n 3260). Valsartan reduced SBP in patients in the upper 3 quartiles but not in patients in the lowest quartile who had a baseline SBP 110 mm Hg. Valsartan was associated with decreases in the risks of first morbid event (HR, 0.74; 95% CI, 0.60 to 0.91; P 0.005) and hospitalization for HF (HR, 0.60; 95% CI, 0.45 to 0.79; P 0.001) in the lowest quartile that were not significantly different than the valsartan effects in the other 3 quartiles combined (first morbid event HR, 0.90; 95% CI, 0.79 to 1.02; P 0.10; and HF hospitalization HR, 0.77; 95% CI, 0.64 to 0.93; P 0.006; nonsignificant interactions). The decrease in SBP from baseline to 4 months was an independent risk factor for subsequent events. When changes in SBP were added to the regression model, the effects of valsartan in the lowest quartile and in the other 3 quartiles combined did not change substantially. Conclusion Baseline SBP and a decrease in SBP over time were risk factors for adverse events in HF. Valsartan reduced SBP but not in the high-risk group of patients who had a baseline SBP 110 mm Hg. The beneficial effects of valsartan did not vary significantly with baseline SBP, and decreases in SBP did not counteract the beneficial effects on HF morbidity rates. (Circ Heart Fail. 2008;1:34-42.) Key Words: heart failure blood pressure clinical trial valsartan outcomes High blood pressure increases the risk of death in the general population, 1,2 and hypertension is the most important population-attributable risk factor for the development of heart failure (HF). 3,4 The benefits of treating hypertension on risks of major cardiovascular events are well established in the absence of systolic HF, and effective lowering of blood pressure is associated with an 50% reduction in the incidence of HF. 5,6 Once HF develops, however, lower blood pressure becomes a risk factor for increased mortality and morbidity rates both in acute decompensated 7,8 and chronic HF The risk associated with elevated blood pressure in patients with systolic dysfunction has not been established. Vasodilators used in the treatment of hypertension, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and a combination of hydralazine and isosorbide, are also effective in reducing mortality and morbidity rates in patients with HF Whether the beneficial effects of these medications on morbidity and mortality rates in patients with HF are modified by initially low or drops in blood pressure is an important clinical issue. Clinical Perspective p 42 The present study is a secondary analysis of the Valsartan Heart Failure Trial (Val-HeFT) database to study the effects of baseline blood pressure and changes in blood pressure over Received August 31, 2007; accepted January 18, From the VA Medical Center, Minneapolis, Minn (I.S.A., T.S.R.); the University of Minnesota, Minneapolis, Minn (I.S.A., T.S.R., J.N.C., S.T.); Geriatric Research Education and Clinical Center, VA Medical Center, Minneapolis, Minn (M.K.); and St Elisabeth Hospital, Tilburg, the Netherlands (N.J.H.). The views expressed in this article are those of the authors and do not necessary represent the views of the Department of Veterans Affairs. Correspondence to Inder S. Anand, MD, FRCP, DPhil (Oxon), VA Medical Center, Cardiology 111-C, One Veterans Dr, Minneapolis, MN anand001@umn.edu 2008 American Heart Association, Inc. Circ Heart Fail is available at DOI: /CIRCHEARTFAILURE
2 Anand et al Effect of Blood Pressure on Heart Failure Outcomes 35 time on the effectiveness of treatment with valsartan on morbidity and mortality in patients with moderate to severe HF. First, we sought to confirm that both lower baseline systolic blood pressure (SBP) and a decrease in SBP over time were independently associated with an increased risk of morbidity and mortality. The interaction between the effects of valsartan and baseline SBP was then examined, controlling for several other known prognostic variables. Finally, to determine whether adjusting for any potentially deleterious drops in SBP during treatment would enhance the apparent beneficial effects of valsartan, we examined how controlling for changes in SBP affected the beneficial effects of valsartan. Methods Study Design and Patient Selection Val-HeFT was a randomized, placebo-controlled, double-blind, multicenter trial in 5010 men and women with symptomatic HF that evaluated the efficacy of the angiotensin receptor blocker valsartan. Details of the study design and protocol have been presented previously. 17 Briefly, patients over 18 years of age who were in stable New York Heart Association class II-IV HF for at least 3 months and who had a left ventricular (LV) ejection fraction 40% and LV internal dimension in diastole/body surface area 2.9 cm/m 2 on echocardiography were eligible. All patients had to be receiving stable pharmacological treatment for HF that could include angiotensin-converting enzyme inhibitors, -blockers, digoxin, diuretics, hydralazine, and/or nitrates. Exclusion criteria included a persistent mean standing SBP 90 mm Hg and serum creatinine 2.0 mg/dl. Eligible patients were stratified according to baseline -blocker therapy and were randomly allocated to receive either oral valsartan or placebo. Treatment with valsartan was initiated at 40 mg twice daily and the dose was doubled every 2 weeks to reach the target dose of 160 mg twice daily, provided SBP was 90 mm Hg, there were no signs or symptoms of hypotension, and increases in serum creatinine levels did not exceed 50% of the baseline value. Blood pressure was measured at each visit with a sphygmomanometer after 5 minutes of rest in the sitting position. The study had 2 primary end points: death and the first morbid event, which was defined as either death, sudden death with resuscitation, hospitalization for HF, or administration of intravenous inotropic or vasodilatory drugs for 4 hours without hospitalization. Hospitalization for HF was a secondary end point. Data Analysis Baseline variables grouped by quartiles of baseline SBP were compared with ANOVA for continuous variables and 2 tests for categorical variables. Time to events in various groups were described with Kaplan-Meier curves. Cox proportional-hazards regression models were used to assess the association between time to death from any cause and baseline SBP, changes in SBP during the first 4 months of follow-up, and treatment with valsartan. Baseline SBP values were grouped into quartiles to examine whether baseline SBP was linearly related to the mortality and hospitalization hazards and to examine the effects of valsartan on SBP. The quartile analysis suggested that the relationships between baseline SBP and hazards were not linear, as most of the increased risk was seen in the lowest quartile (quartile 1 [Q1]: SBP 110 mm Hg). Rather than trying to model a continuous nonlinear relationship, all further analyses were simply carried out comparing Q1 with the other 3 quartiles (Q2, Q3, and Q4) combined. Analyses were repeated using time to first morbid event and first hospitalization for HF as the dependent variable. All of the regression models included baseline age, New York Heart Association class, ischemic etiology, history of hypertension, diabetes, body mass index, pulse, LV ejection fraction, serum sodium, creatinine, uric acid, brain natriuretic peptide, aldosterone, plasma renin activity, hemoglobin, and use of angiotensinconverting enzyme inhibitors, diuretics, digoxin, and -blockers as covariates. When change in blood pressure over the first 4 months was included in the models, all subjects with fatal (n 154) or nonfatal events (n 332) that occurred during the first 4 months of follow-up were excluded. The changes in SBP from baseline to month 4, month 12, and end of study in the 2 treatment groups were compared at each time point with a 2-sample t test rather than ANOVA to minimize loss of information over time due to deaths and censored follow-up. SPSS statistical software (version 15; SPSS Inc, Chicago, Ill) was used for all analyses. A probability value 0.05 was considered significant without adjustment for making multiple comparisons. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written. Results Patient Characteristics The baseline blood pressure (mean standard deviation) in the overall population was mm Hg systolic and mm Hg diastolic (n 5010). Comparison of SBP quartiles in Table 1 indicates that lower SBP was associated with younger age, lower body mass index, lower LV ejection fraction, greater LV internal dimension in diastole, higher levels of aldosterone and plasma renin activity, and lower hemoglobin levels. Lower SBP was also associated with worse New York Heart Association class and Minnesota Living with Heart Failure Questionnaire (MLHF) scores, along with more prevalent use of diuretics, digoxin, and spironolactone. The mean SBP of 149 mm Hg among the large number of patients in Q4 (SBP 135 mm Hg) is remarkable for patients with documented systolic dysfunction who were often treated with medications that lower blood pressure. Baseline Systolic Blood Pressure Related to Morbidity and Mortality Unadjusted time to death, first morbid event, and hospitalization for HF within quartiles of baseline SBP are shown in Figure 1. The risks of all events were similar in the upper 3 quartiles of SBP and increased only in the Q1, suggesting that baseline SBP was not linearly related to the risk (hazard) of death or hospitalization for HF. We did not fit nonlinear models to this relationship. The Cox multivariable model for baseline SBP quartiles is shown in Table 2. With Q3 (patients with normal SBP) as the reference group, only patients in the Q1 were found to have an increased risk of first morbid event and hospitalization for HF, with a trend for an increase risk for death. The upper quartile that contained many patients with elevated SBP was not associated with increased risk. Given these findings, the upper 3 quartiles were collapsed into 1 group for further analyses comparing Q1 with Q2, Q3, and Q4 combined. Patients with baseline SBP in the lowest quartile (Q1: 110 mm Hg) had a significantly increased adjusted risk of death (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.03 to 1.43; P 0.02), first morbid event (HR, 1.25; 95% CI, 1.10 to 1.40; P 0.001), and hospitalization for HF (HR, 1.45; 95% CI, 1.22 to 1.73; P 0.001) compared with patients in the upper 3 quartiles (Table 2). Thus, a low baseline SBP was an independent risk factor for morbidity and mortality in this patient population.
3 36 Circ Heart Fail May 2008 Table 1. Baseline Characteristics by Quartile of SBP Quartile 1 Quartile 2 Quartile 3 Quartile 4 Quartiles 2, 3, and 4 Combined No Age, y Female White Ischemic etiology Nonischemic etiology Diabetes Atrial fibrillation Mean SBP, mm Hg Mean DBP, mm Hg Heart rate, bpm NYHA III/IV MLHFQ History of PND Elevated JVP Peripheral edema Weight, kg BMI, kg/m egfr Serum albumin, g/dl S3 presence LVEF LVIDd/BSA Background therapy ACE inhibitors Blockers Diuretics Digoxin* Aspirin Statins Spironolactone Hemoglobin, g/dl* lncrp lnnorepinephrine lnbnp lnaldosterone* lnpra* Values are expressed as mean SD or %. DBP indicates diastolic blood pressure; NYHA, New York Heart Association functional class; MLHFQ, Minnesota Living with Heart Failure Questionnaire; PND, paroxysmal nocturnal dyspnea; JVP, jugular venous pressure; BMI, body mass index; egfr, estimated glomular filtration rate; LVEF, left ventricular ejection fraction; LVIDd, left ventricle internal dimension in diastole; BSA, body surface area; ACE, angiotensin-converting enzyme; CRP, C-reactive protein; BNP, brain natriuretic peptide; and PRA, plasma renin activity. *P 0.05, P for differences between quartiles. P 0.05, P 0.01 between Q1 and Q2, Q3, and Q4 combined. Effect of Baseline Systolic Blood Pressure on Effectiveness of Valsartan In the overall population, valsartan use was not associated with a reduction in the risk of death but it did cause a 13.3% reduction in risk of first morbid event (HR, 0.87; 95% CI, 0.77 to 0.97) and a 27.5% reduction in risk for first hospitalization for worsening HF (HR, 0.73; 95% CI, 0.64 to 0.84). 17 When the effects of valsartan were estimated separately in patients with baseline SBP in Q1 and in those with baseline SBP the upper 3 SBP quartiles combined, use of valsartan was associated with a 26% decrease in risk of first morbid event in the Q1 patients (HR, 0.74; 95% CI, 0.60 to 0.91; P 0.005), compared with a 10% decrease in the combined Q2, Q3, and Q4 group (HR, 0.90; 95% CI, 0.79 to 1.02;
4 Anand et al Effect of Blood Pressure on Heart Failure Outcomes 37 % Survival % Event Free Survival % Hospitalizations for Heart Failure SBP <110 mmhg SBP >110 <121 mmhg SBP >121 <135 mmhg SBP >135 mmhg Time to Death Months Since Randomization Time to First Morbid Event Months Since Randomization Time to Hospitalization Months Since Randomization Figure. Kaplan-Meier curves for time to death, first morbid event, and hospitalization for HF by quartile of baseline systolic blood pressure. P 0.10). The test for interaction between the effects of valsartan treatment and baseline SBP was not significant, however, as shown in Table 3. Similarly, valsartan caused a 40% decrease in risk of first hospitalization for HF in Q1 patients (HR, 0.60; 95% CI, 0.45 to 0.79, P 0.001) and a 23% decrease in patients in the upper 3 quartiles (HR, 0.77; 95% CI, 0.64 to 0.93; P 0.006), with interaction that was again not significant. Effect of Valsartan on Systolic Blood Pressure Overall, treatment with valsartan caused a significant placebo corrected decrease in SBP (mean, [95% CI]) of 4.0 ( 3.1 to 4.6), 3.9 ( 2.9 to 4.9), and 3.4 ( 2.4 to 4.3) mm Hg at 4 months, 12 months, and the end point, respectively (P at all time points). The change in SBP at 4 months with valsartan by quartiles of baseline SBP is shown in Table 4. Treatment with valsartan did not lower SBP in Q1 ( 110 mm Hg). In fact, the mean SBP increased in both the placebo and valsartan groups as one might expect with regression to the mean. However, the increase in SBP in Q1 was significantly greater in the placebo group (P 0.001). In contrast to the lowest baseline SBP quartile, SBP fell in the other 3 combined quartiles in both treatment groups at 4 months, with a significantly greater decrease in the valsartan group. Because the use of valsartan in patients with extremely low SBP may be a concern to the clinicians, we also compared the response to valsartan with the response to placebo in 317 patients whose baseline SBP was 100 mm Hg (valsartan group mean SBP 95 3 mm Hg, n 170; placebo group mean SBP 95 3 mm Hg, n 147). In this group as well, SBP increased in both the valsartan (5 13 mm Hg) and placebo (8 12 mm Hg) groups, and the increase was significantly greater in the placebo group (Table 4). Safety Profile of Valsartan in Patients With Low Versus High Baseline SBP Overall, the mean change from baseline to 4 months was greater in the valsartan group than in the placebo group for blood urea nitrogen ( versus mmol/dl P 0.001), serum creatinine ( versus mmol/ dl, P 0.001), and serum potassium ( versus decrease of mmol/dl, P 0.001). However, the effect of valsartan on these parameters was similar in low (Q1) and high (Q2, Q3, and Q4) SBP groups (blood urea nitrogen versus mmol/l; creatinine versus mmol/dl; and potassium versus mmol/l; all P not significant). More patients discontinued the randomized treatment because of hypotension in Q1 (2.9% in valsartan group versus 1.4% in placebo group; P 0.001) than in the other quartiles combined (0.7% in valsartan group versus 0.2% in placebo group; P 0.001). Changes in Systolic Blood Pressure Related to Morbidity and Mortality When the change in SBP over the first 4 months was analyzed as a continuous variable in a multivariable Cox regression model ignoring treatment, a 1-mm Hg increase in SBP was associated with a significant decrease in the risk of death, first morbid event, and hospitalizations for HF in the entire population (Table 5). The interaction between the baseline SBP quartile groups and the change in SBP was not significant for any end point, suggesting that the beneficial effect associated with an increase in SBP over time was not different in the 2 groups defined by baseline SBP (Table 5). Thus, both low baseline SBP and a decrease in SBP over time were associated with an increase in subsequent HF morbidity.
5 38 Circ Heart Fail May 2008 Table 2. Adjusted Hazard Ratios (95% Confidence Interval) for Mortality, First Morbid Event, and Hospitalizations for HF in Patients Grouped by Baseline SBP Mean Baseline SBP, Mean SD Mortality, HR First Morbid Event, HR Hospitalization for HF, HR No. of Patients SBP Quartiles Q1: 110 mm Hg (0.98 to 1.47) 1.24 (1.05 to 1.45) 1.44 (1.16 to 1.79) P Q2: 110 mm Hg and 121 mm Hg (0.82 to 1.23) 0.97 (0.83 to 1.14) 1.01 (0.81 to 1.26) P Q3: 121 mm Hg and 135 mm Hg Reference group Reference group Reference group P Q4: 135 mm Hg (0.76 to 1.16) 0.99 (0.84 to 1.17) 0.95 (0.71 to 1.20) P Q1 versus Q2, Q3, and Q4 combined Q (1.03 to 1.43) 1.25 (1.10 to 1.4) 1.45 (1.22 to 1.73) P Q2, Q3, and Q4 combined Reference group Reference group Reference group Covariates used in the Cox regression model: age, New York Heart Association class, origin, history of hypertension, diabetes, body mass index, pulse, LV ejection fraction, serum sodium, creatinine, uric acid, brain natriuretic peptide, aldosterone, plasma renin activity, hemoglobin, and use of an angiotensin-converting enzyme inhibitor, diuretics, digoxin, or -blockers. No. in each groups is for those with all covariates. P values are against the reference groups. HR indicates hazard ratio. Effects of Valsartan Treatment Adjusted for Change in Systolic Blood Pressure Because valsartan caused a significant decrease in SBP in baseline Q2, Q3, and Q4 and a smaller increase in SBP in Q1 compared with placebo throughout the study, and because a decrease in SBP was associated with worse outcomes regardless of baseline SBP, we examined whether controlling for the change in SBP after 4 months would alter the apparent effectiveness of valsartan from 4 months to the end of follow-up. When the change in SBP was added to the regression model, the beneficial effects of valsartan on first morbid event and hospitalizations for HF tended to increase in Q1, and to a lesser extent in Q2, Q3, and Q4 (Table 6); however, the blood pressure lowering effect of valsartan did not deeply undermine its beneficial effects. Furthermore, there was no significant interaction between treatment and change in blood pressure on any of the outcomes, suggesting that the effect of valsartan was not greatly modified by changes in SBP. Discussion The present analysis of Val-HeFT data confirms that low SBP is independently associated with an increase in the risk of mortality and morbidity in patients with moderate to severe chronic HF. 7,9 11 The increased risk did not appear to be linear across all levels of baseline SBP and was observed mainly in patients with a SBP in the lowest quartile ( 110 mm Hg). A decrease in SBP over time was also found to increase the subsequent risk of adverse outcomes. It is noteworthy that approximately 25% of patients in the present study, all of whom had documented LV systolic dysfunction and were being treated with a diuretic (84%), an Table 3. Effect of Valsartan Versus Placebo on Mortality, First Morbid Event, and Hospitalizations for HF in Patients Grouped by Baseline SBP Mean Baseline SBP, mm Hg Mean SD No. of Patients Placebo Valsartan Placebo Valsartan Mortality, HR Q (0.63 to 1.06) First Morbid Event, HR 0.74 (0.60 to 0.91) Hospitalization for HF, HR 0.60 (0.45 to 0.79) P Q2, Q3, and Q4 combined (0.88 to 1.23) 0.90 (0.79 to 1.02) 0.77 (0.64 to 0.93) P Interaction P The Hs (95% CIs) have been adjusted for all covariates. Covariates used in the Cox regression model: age, New York Heart Association class, origin, history of hypertension, diabetes, body mass index, pulse, LV ejection fraction, serum sodium, creatinine, uric acid, brain natriuretic peptide, aldosterone, plasma renin activity, hemoglobin, and use of an angiotensin-converting enzyme inhibitor, diuretics, digoxin, or -blockers. No. in each groups is for those with all covariates. HR indicates hazard ratio.
6 Anand et al Effect of Blood Pressure on Heart Failure Outcomes 39 Table 4. Effects of Valsartan on SBP at 4 Months by Quartile of Baseline SBP No. of Patients Mean Baseline SBP Mean Change in SBP Placebo-Corrected Change Quartiles of Baseline Systolic Blood Pressure Q1: 110 mm Hg Valsartan ( 6.4 to 3.5) Placebo Q2: 110 mm Hg and 121 mm Hg Valsartan ( 4.8 to 1.7) Placebo Q3: 121 mm Hg and 135 mm Hg Valsartan ( 6.7 to 3.5) Placebo Q4: 135 mm Hg Valsartan ( 5.4 to 1.4) Placebo Q1 versus Q2 Q3 Q4 Q1 Valsartan ( 6.4 to 3.5 Placebo Q2 Q3 Q4 Valsartan ( 4.6 to 2.6) Placebo SBP 100 mm Hg Valsartan ( 6.2 to 0.5)* Placebo Values are expressed as n, mean SD. *P 0.05, P 0.01 for change in SBP comparing valsartan to placebo groups. angiotensin-converting enzyme inhibitor (92%), and sometimes a -blocker (35%), still had SBP 135 mm Hg (mean 149 mm Hg). The reason for the high SBP is not obvious. These patients tended to be older, to have better LV function, and to have slightly less medication use than others in the study. Interestingly, these patients did not have a significantly increased risk of adverse events. In the African American Heart Failure Trial (A-HeFT), approximately 25% patients with systolic dysfunction had similarly elevated blood pressure at baseline. 12 Similar findings of elevated SBP have also been reported recently in patients admitted with acute HF from the Organized Program To Initiate life-saving treatment in hospitalized patients with Heart Failure (OPTIMIZE-HF) registry. In this registry, the majority of patients with elevated SBP had preserved LV function. Although the pathophysiology of systolic hypertension might be different in patients with preserved LV systolic function, if elevated SBP is common among patients with chronic HF and LV systolic dysfunction and the elevated SBP is not associated with increased risk of adverse events (although the risk of stroke Table 5. Effect of Change in SBP From Baseline to 4 Months on the Adjusted HRs (95% CIs) for Mortality, First Morbid Event, and Hospitalizations for HF Analyzed as a Continuous Variable in Patients Grouped by Quartile No. of Patients Mortality, HR First Morbid Event, HR Hospitalization for HF, HR Continuous variable (0.988 to 0.999) (0.987 to 0.996) (0.983 to 0.995) P Q1 versus Q2 Q3 Q4 Q (0.986 to 1.01) (0.983 to 1.004) (0.972 to 0.999) P Q2 Q3 Q (0.986 to 0.998) (0.986 to 0.996) (0.983 to 0.996) P Interaction P Covariates used in the Cox regression model: baseline SBP, age, New York Heart Association class, origin, history of hypertension, diabetes, body mass index, pulse, LV ejection fraction, serum sodium, creatinine, uric acid, brain natriuretic peptide, aldosterone, plasma renin activity, hemoglobin, and use of an angiotensin-converting enzyme inhibitor, diuretics, digoxin, or -blockers. No. in each groups is for those with all covariates. HR indicates hazard ratio.
7 40 Circ Heart Fail May 2008 Table 6. Effect of Controlling for Changes in SBP on the Effect of Valsartan on Mortality, First Morbid Event, and Hospitalizations for HF Placebo Versus Valsartan, Mean Difference in SBP, mm Hg Mortality* First Morbid Event* Hospitalization for HF* Baseline SBP Q1 (n 853) Without change in SBP in model 0.82 (0.63 to 1.06) 0.74 (0.60 to 0.91) 0.60 (0.45 to 0.79) P With change in SBP in model (0.54 to 1.03) 0.63 (0.49 to 0.82) 0.52 (0.37 to 0.73) P Baseline SBP Q2 Q3 Q4 (n 3044) Without change in SBP in model 1.07 (0.87 to 1.29) 0.88 (0.76 to 1.02) 0.75 (0.62 to 0.91) P With change in SBP in model (0.86 to 1.28) 0.83 (0.71 to 0.97) 0.69 (0.56 to 0.84) P *HR from Cox regression model; see Data Analysis section for a list of covariates. Groups include only those who had a value for all covariates. could not be assessed), one wonders whether the high SBP should or could be decreased. This important question needs to be addressed by further research. Although the beneficial effects of valsartan in reducing the number of morbid events over time and of hospitalizations for HF tended to be relatively higher in the patients with the baseline SBP 110 mm Hg (Q1) as compared with those with SBP above 110 mm Hg, statistical test for interaction between treatment and baseline SBP did not detect a significant difference in effect in the 2 subgroups. Interestingly, valsartan did not actually decrease SBP in patients with the lowest pretreatment values, including those in Q1 with a SBP 110 mm Hg or even the subgroup with a SBP 100 mm Hg, even though valsartan was associated with a smaller increase in SBP as compared with placebo. In contrast, valsartan did cause a significant decrease in SBP in patients with higher baseline SBP that could have potentially counteracted its beneficial effects on morbidity rates. However, the present analysis did not indicate that the benefits of valsartan depended on baseline SBP or changes in SBP during the first 4 months of treatment, suggesting dissociation between the effects of valsartan on SBP and clinical outcomes. It should be emphasized, however, that these conclusions are based on the lack of significance for interaction. Although interaction tests can be useful exploratory tools, the lack of statistical significance for interaction tests may be partially due to their relatively low power. Thus, any inference based on interaction test results should be made with caution. The observation that blood pressure did not actually decrease in the group with low initial SBP suggests that the addition of valsartan was usually well tolerated by patients with moderate to severe chronic HF. Low SBP blood pressure should not preclude a trial of these agents that appear to benefit all patients. Is there a threshold SBP below which the use of an angiotensin receptor blocker is associated with deleterious outcomes? Although the present study was not designed to address this question, we did find that even in the small subgroup of 317 patients with a SBP between 90 and 100 mm Hg, valsartan appeared to have been well tolerated, on average, without frequent deleterious drops in blood pressure. Because patients with low initial SBP are at a greater risk of HF morbidity and mortality, and because a trend for greater risk reduction in morbidity was seen with valsartan for the low SBP patients (even though the risk reduction for HF hospitalization was significant for both low and high SBP patients), patients with low SBP could be expected to be more likely to benefit from this treatment. Moreover, the increases in serum creatinine, blood urea nitrogen, and potassium were no different in patients in baseline SBP Q1 or than those in Q2, Q3, and Q4, suggesting that introduction of valsartan even in patients with low SBP may not precipitate major adverse effects. However, a patient s baseline SBP had to be 90 mm Hg to be eligible for this clinical trial or for an increase in the dose of the study medication. Thus, these data cannot address the use or benefits of valsartan in patients with HF and a SBP less than this level. If low baseline SBP and a decrease in SBP over time are associated with worse outcomes, how can we explain the apparent dissociation between the blood pressure lowering effects of valsartan and clinical outcomes? The fact that valsartan did not lower blood pressure in patients with a low baseline SBP could be explained by an improvement in the hemodynamics, although these were not measured in the present study. In patients with chronic HF, a low stroke volume threatens the arterial blood pressure and leads to a baroreceptor-mediated activation of several vasoconstrictive neurohormones that help to preserve blood pressure by increasing arterial impedance. 19 The increase in impedance is, however, deleterious to the failing heart and further reduces the stroke volume, worsening hypotension. Vasodilators such as sodium nitroprusside reverse the functional abnormalities acutely by improving stroke volume and may increase blood pressure. 10,20,21 Thus, the vasodilatory effects of valsartan might have lowered arterial impedance in patients with the
8 Anand et al Effect of Blood Pressure on Heart Failure Outcomes 41 lowest SBP who would be expected to have the highest impedance, thereby increasing the cardiac output and maintaining blood pressure. Over the long term, valsartan use was associated with an improvement in LV ejection fraction 22 and a decrease in the levels of several neurohormones, including brain natriuretic peptide, norepinephrine, and aldosterone. 23,24 Thus, the dual effects of lowering impedance (BP-lowering effect) and improving LV structural remodeling might have contributed to the beneficial effects of valsartan on hemodynamics and subsequently to reduced morbidity and mortality. In conclusion, the present secondary analysis of data from a randomized controlled clinical trial suggests that patients with low systolic blood pressure can benefit from valsartan therapy without an inordinate risk of deleterious hypotension. Patients with low SBP are at least as likely as and perhaps more likely to benefit from valsartan therapy as those with normal or high pretreatment blood pressures. Patients with low blood pressure are at the highest risk and, therefore, have the greatest need for aggressive therapy. Judicious use of valsartan in such patients is more likely to produce benefit than use in those with higher blood pressures, although patients with low or high SBP appear to benefit. However, the data were not sufficient to determine whether these findings are generalizable to patients with SBP well below 100 mm Hg. Regardless, blood pressure reduction does not seem to greatly counteract the favorable effects of valsartan on hospitalization for HF and morbidity and cannot be used as a surrogate for efficacy. Many patients in the present analysis had HF, systolic dysfunction, and prescriptions for antihypertensive medications but still had elevated SBP; however, they were not at increased risk of adverse events. Because reductions in SBP tended to be associated with increased risk, further research is needed to determine whether the SBP should be reduced in patients with these characteristics and how this might be achieved, if desirable. Finally, it is important to emphasize that findings of the present study do not apply to patients with acute decompensated HF. Sources of Funding Novartis Pharmaceutical provided a grant for the study. Resources of the Minneapolis VA Medical Center supported this analysis in part. Dr Rector was supported by VA Clinical Science and Health Services Research & Development Grants 04S-CRCOE-001 and HFP Disclosures Drs Anand, Holwerda, and Cohn received research grants and honoraria from Novartis. The other authors report no conflicts. References 1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (published correction appears in Lancet. 2003;361:1060). Lancet. 2002;360: World Health Organization. World Health Report 2002; Reducing Risk, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D; Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106: Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338: SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265: Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293: Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290: Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95: Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, Adams KF, Olukotun AY, Worcel M, Cohn JN. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol. 2007;49: Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113: Taylor AL, Ziesche S, Yancy C, Carson P, D Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African- American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure (published correction appears in N Engl J Med. 2005;352:1276). N Engl J Med. 2004;351: Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362: The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325: Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314: Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345: Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296: Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin: studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80: Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med. 1977;297: Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med. 1977;297:27 31.
9 42 Circ Heart Fail May Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN; Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40: Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R; Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003;108: Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN; Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106: CLINICAL PERSPECTIVE Lowering high blood pressure greatly reduces the incidence of heart failure. In the presence of heart failure with systolic dysfunction, however, low blood pressure and drops in blood pressure are associated with increased risk of hospitalization and death. Many effective medications that are used for heart failure, including those that decrease angiotensin II, reduce blood pressure, which could reduce their beneficial effects. Concerns about hypotensive effects often limit use of these medications. The present secondary analysis of data from the Valsartan Heart Failure trial indicates that neither a low pretreatment systolic blood pressure (SBP) nor changes in SBP reduced the beneficial effects of valsartan. As expected, valsartan did reduce SBP in patients in the upper 3 quartiles of SBP but not those in the lowest quartile who had a baseline SBP between 90 and 110 mm Hg. Valsartan reduced the risk of hospitalization for heart failure and the first morbid event in the lowest SBP quartile and the other 3 quartiles. Adjustments for the changes in SBP on therapy did not substantially reduce these beneficial effects. Judicious use of valsartan should be considered for patients who present with low SBP and have the highest risk of hospitalization and death.
Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme Inhibitors
Journal of the American College of Cardiology Vol. 40, No. 8, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02304-5
More informationJournal of the American College of Cardiology Vol. 52, No. 24, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 52, No. 24, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.09.011
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationChanges in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) Inder S. Anand, MD, DPhil; Lloyd D. Fisher, PhD; Yann-Tong
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationn Kristensen, S. L., Jhund, P. S., Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., Komajda, M., Cleland, J. G.F., Carson, P. E., and McMurray, J. J.V. (2015) Relative importance of history of heart
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationMayo Clin Proc, March 2003, Vol 78 Role of ARBs in Treatment of Heart Failure 335 system, tissue-based RAS has long-term effects that can modify cardi
334 Concise Review for Clinicians Therapeutic Role of Angiotensin II Receptor Blockers in the Treatment of Heart Failure Concise Review for Clinicians PRERANA MANOHAR, MD, AND ILEANA L. PIÑA, MD Angiotensin
More informationFor personal use. Only reproduce with permission from The Lancet publishing Group. Summary
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Christopher
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationEfficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis
Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Dipak Kotecha, MD PhD on behalf of the Selection of slides presented at the European
More informationMetoprolol CR/XL in Female Patients With Heart Failure
Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Jalal K. Ghali, MD; Ileana L.
More informationImpact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016
Impact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016 National Minority Quality forum APRIL 11, 2016 Washington,D.C. Keith C. Ferdinand,
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationPOSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002)
POSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002) Well designed, large scale, randomized double-blind, placebo-controlled trials have validated the efficacy of the ACE-inhibitor enalapril in
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationEffect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial
Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial Aldo P. Maggioni, MD, FESC Associazione Nazionale Medici
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationRACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION
RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION DANIEL L. DRIES, M.D., M.P.H., DEREK V. EXNER, M.D., BERNARD J. GERSH,
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationNew CHF Patient in my Office: What Should I Do?
New CHF Patient in my Office: What Should I Do? Joseph Mishkin MD FACC Advanced Heart Failure, Transplantation and Mechanical Circulatory Support No disclosures Disclosures Clinical Presentation 38 year
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationMihai Gheorghiade MD
Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen J Greene MD; Javed Butler MD MPH MBA; Gerasimos Filippatos
More informationHF-PEF: Symptoms, quality of life and mortality/morbidity
HF-PEF: Symptoms, quality of life and mortality/morbidity May 21, 2011 John McMurray, MD Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham & Women s Hospital Boston; Visiting Professor of Medicine,
More informationCardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
More informationTreating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks
Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks 12th Annual Leadership Summit on Health Disparities & Congressional Black Caucus Spring Health
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationThe role of angiotensin II receptor blockers in the management of heart failure
European Heart Journal Supplements (2005) 7 (Supplement J), J10 J14 doi:10.1093/eurheartj/sui057 The role of angiotensin II receptor blockers in the management of heart failure John J.V. McMurray* Department
More informationClinical Risk Prediction Tools in Patients Hospitalized With Heart Failure
ManageMent Update Clinical Risk Prediction Tools in Patients Hospitalized With Heart Failure Gregg C. Fonarow, MD, FACC, FAHA Ahmanson UCLA Cardiomyopathy Center, University of California Los Angeles,
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationMeasuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D.
Measuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D. Chronology of ISDN/Hydralazine ISDN/HYD V-HeFT I BIDIL Sub-group
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationTreatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationImplementing the CardioMEMS HF System into the Management of Heart Failure Patients
Implementing the CardioMEMS HF System into the Management of Heart Failure Patients Robert W. Hull MD FACC Associate Professor of Medicine WVU Heart Institute Co-director, Arrhythmia Service Director,
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationSelecting patients for heart transplantation: Comparison of the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM)
http://www.jhltonline.org Selecting patients for heart transplantation: Comparison of the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM) Ayumi Goda, MD, PhD, a,b Paula Williams,
More informationHeart Failure with Preserved Ejection Fraction: Mechanisms and Management
Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Jay N. Cohn, M.D. Professor of Medicine Director, Rasmussen Center for Cardiovascular Disease Prevention University of Minnesota
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationDisclosure Information : No conflict of interest
Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationImpact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,
More informationIntroduction: Clinical Trials: Assessing Safety and Efficacy for a Diverse Population
Introduction: Clinical Trials: Assessing Safety and Efficacy for a Diverse Population FDA and JHU-CERSI White Oak, Maryland Wednesday, December 2, 2015 Keith C. Ferdinand, MD, FACC,FAHA,FNLA,FASH Professor
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial John J V McMurray, Jan
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationThe value of angiotensin-converting enzyme (ACE) inhibitors
New Drugs and Technologies Which Inhibitor of the Renin Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? John J.V. McMurray, MD; Marc A. Pfeffer, MD, PhD; Karl
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists
Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More information